DK0792154T3 - Sammensætning af cisplatin i kombination med 2,2'-dithio-bis(ethansulfonat) (dimesna) - Google Patents

Sammensætning af cisplatin i kombination med 2,2'-dithio-bis(ethansulfonat) (dimesna)

Info

Publication number: DK0792154T3
Authority: DK; Denmark
Prior art keywords: dithio; bis; cisplatin; dimesna; ethanesulfonate
Prior art date: 1994-11-14

Application number

DK95939282T

Other languages

English (en)

Inventor

Peddaiahgari Seetharamulu

Frederick Herman Hausheer

Kochat Haridas

Dhanabalan Murali

Dasharatha Gauravaram Reddy

Original Assignee

Bionumerik Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-11-14

Filing date

1995-11-14

Publication date

2003-08-04

1995-11-14 Application filed by Bionumerik Pharmaceuticals Inc filed Critical Bionumerik Pharmaceuticals Inc

2003-08-04 Application granted granted Critical

2003-08-04 Publication of DK0792154T3 publication Critical patent/DK0792154T3/da

Links

BYUKOOOZTSTOOH-UHFFFAOYSA-N 2-(2-sulfoethyldisulfanyl)ethanesulfonic acid Chemical compound OS(=O)(=O)CCSSCCS(O)(=O)=O BYUKOOOZTSTOOH-UHFFFAOYSA-N 0.000 title abstract 3
239000000203 mixture Substances 0.000 title abstract 3
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 title abstract 2
229960004316 cisplatin Drugs 0.000 title abstract 2
229950009278 dimesna Drugs 0.000 title 1
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 abstract 2
238000009472 formulation Methods 0.000 abstract 2
206010028980 Neoplasm Diseases 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
231100000268 induced nephrotoxicity Toxicity 0.000 abstract 1
238000007911 parenteral administration Methods 0.000 abstract 1
CLSUSRZJUQMOHH-UHFFFAOYSA-L platinum dichloride Chemical compound Cl[Pt]Cl CLSUSRZJUQMOHH-UHFFFAOYSA-L 0.000 abstract 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Inorganic Chemistry (AREA)
Emergency Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Toxicology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

DK95939282T 1994-11-14 1995-11-14 Sammensætning af cisplatin i kombination med 2,2'-dithio-bis(ethansulfonat) (dimesna) DK0792154T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/338,379 US5789000A (en)	1994-11-14	1994-11-14	Sterile aqueous parenteral formulations of cis-diammine dichloro platinum
PCT/EP1995/004490 WO1996014852A1 (en)	1994-11-14	1995-11-14	Composition of cisplatin in combination with 2,2'-dithio-bis(ethanesulfonate) (dimesna)

Publications (1)

Publication Number	Publication Date
DK0792154T3 true DK0792154T3 (da)	2003-08-04

Family

ID=23324592

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK95939282T DK0792154T3 (da)	1994-11-14	1995-11-14	Sammensætning af cisplatin i kombination med 2,2'-dithio-bis(ethansulfonat) (dimesna)

Country Status (13)

Country	Link
US (5)	US5789000A (da)
EP (1)	EP0792154B1 (da)
JP (3)	JP4171526B2 (da)
KR (1)	KR100411380B1 (da)
CN (2)	CN1165483B (da)
AT (1)	ATE237337T1 (da)
AU (1)	AU706181B2 (da)
CA (1)	CA2202170C (da)
DE (1)	DE69530412T2 (da)
DK (1)	DK0792154T3 (da)
ES (1)	ES2191717T3 (da)
PT (1)	PT792154E (da)
WO (1)	WO1996014852A1 (da)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6025488A (en) *	1994-11-14	2000-02-15	Bionumerik Pharmaceuticals, Inc.	Formulations and methods of reducing toxicity of antineoplastic agents
US5919816A (en) *	1994-11-14	1999-07-06	Bionumerik Pharmaceuticals, Inc.	Formulations and methods of reducing toxicity of antineoplastic agents
US5789000A (en) *	1994-11-14	1998-08-04	Bionumerik Pharmaceuticals, Inc.	Sterile aqueous parenteral formulations of cis-diammine dichloro platinum
ES2170414T3 (es) *	1996-09-23	2002-08-01	Bionumerik Pharmaceuticals Inc	Reduccion de efectos toxicos del carboplatino usando ditioeteres.
US6037336A (en) *	1996-09-23	2000-03-14	Bionumerik Pharmaceuticals, Inc.	Reducing toxic effects of carboplatin using dithioethers
US6312734B1 (en) *	1998-11-23	2001-11-06	Novelos Therapeutics, Inc.	Methods for production of the oxidized glutathione composite with cis-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells
RU2144374C1 (ru) *	1998-11-23	2000-01-20	Закрытое акционерное общество "ВАМ"	Способ получения композита окисленного глутатиона с cis-диаминодихлорплатиной и фармацевтических композиций на его основе, регулирующих метаболизм, пролиферацию, дифференцировку и механизмы апоптоза нормальных и трансформированных клеток
US20070142267A1 (en) *	1998-11-23	2007-06-21	Novelos Therapeutics, Inc.	Methods for production of the oxidized glutathione composite with CIS-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells
US6197831B1 (en) *	1999-02-09	2001-03-06	Bionumerik Pharmaceuticals, Inc.	Method of treating septic shock
US6034126A (en) *	1999-05-24	2000-03-07	Bionumerik Pharmaceuticals, Inc.	Method for treating glycol poisoning
AU775373B2 (en)	1999-10-01	2004-07-29	Immunogen, Inc.	Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US6156350A (en) *	1999-12-02	2000-12-05	Corazon Technologies, Inc.	Methods and kits for use in preventing restenosis
EP1328253B1 (en)	2000-04-26	2006-03-22	Oregon Health Sciences University	Administration of a thiol-based chemoprotectant compound
GB0011903D0 (en) *	2000-05-18	2000-07-05	Astrazeneca Ab	Combination chemotherapy
CA2426762A1 (en) *	2000-11-02	2002-05-10	Sloan-Kettering Institute For Cancer Research	Methods for enhancing the efficacy of cytotoxic agents through the use of hsp90 inhibitors
US6540733B2 (en) *	2000-12-29	2003-04-01	Corazon Technologies, Inc.	Proton generating catheters and methods for their use in enhancing fluid flow through a vascular site occupied by a calcified vascular occlusion
EP1351677A4 (en) *	2001-01-19	2009-08-19	Bionumerik Pharmaceuticals Inc	CANCER TREATMENT METHOD
JP2005508838A (ja) *	2001-03-23	2005-04-07	アフトンコーポレーション	膵癌の組合せ治療
US20090191232A1 (en) *	2001-05-04	2009-07-30	Gevas Philip C	Combination therapy for the treatment of tumors
JP2004536835A (ja) *	2001-07-09	2004-12-09	アフトンコーポレーション	肝臓、肺および食道の癌性ならびに前癌性状態の治療および防止
US6352979B1 (en) *	2001-08-20	2002-03-05	Lucinda Lizcano	Method of treating snakebite and complications resulting therefrom
SK1472004A3 (en) *	2001-09-24	2004-10-05	Tosk Inc	Reduced toxicity cisplatin formulations and methods for using the same
US7176192B2 (en) *	2001-10-26	2007-02-13	Bionumerik Pharmaceuticals, Inc.	Method for treating patients for radiation exposure
US6596320B1 (en) *	2002-01-11	2003-07-22	Bionumerik Pharmaceuticals, Inc.	Method for treating cancer having greater efficacy and reduced adverse effects
CA2480045C (en) *	2002-03-28	2013-09-24	Medical College Of Ohio	Method and compositions for the diagnosis and treatment of non-small cell lung cancer using gene expression profiles
US8710095B2 (en) *	2002-04-30	2014-04-29	Bionumerik Pharmaceuticals, Inc.	Drugs for prophylaxis or mitigation of taxane-induced neurotoxicity
US20040014730A1 (en) *	2002-07-10	2004-01-22	Frederick Hausheer	Formulations and methods of reducing toxicity of anti-infective agents
MXPA05006721A (es) *	2002-12-21	2005-09-30	Bionumerik Pharmaceuticals Inc	Metodo para tratamiento de pacientes expuestos a agentes quimicos toxicos.
WO2004094409A1 (en) *	2003-03-27	2004-11-04	Lankenau Institute For Medical Research	Novel ido inhibitors and methods of use
CA2548497C (en) *	2003-12-17	2009-06-09	Bionumerik Pharmaceuticals, Inc.	Process for synthesizing disulfides
EP1730193A2 (en) *	2004-03-29	2006-12-13	Receptor Biologix, Inc.	Monoclonal antibodies to gastrin hormone
US20090111735A1 (en) *	2004-05-12	2009-04-30	Bionumerik Pharmaceuticals, Inc.	Compounds and methods for reducing undesired toxicity of chemotherapeutic agents
US20050256055A1 (en) *	2004-05-12	2005-11-17	Hausheer Frederick H	Compounds and methods for reducing undesired toxicity of chemotherapeutic agents
US7282602B2 (en) *	2004-09-21	2007-10-16	Bionumerik Pharmaceuticals, Inc.	Medicinal disulfide salts
US7235589B2 (en)	2004-09-21	2007-06-26	Bio Numerik Pharmaceuticals, Inc.	Method of treating patients undergoing kidney dialysis
US20060063742A1 (en) *	2004-09-21	2006-03-23	Hausheer Frederick H	Method of treatment for or protection against lymphedema
KR101333168B1 (ko)	2004-09-22	2013-11-28	리셉터 바이오로직스 인크	프로가스트린에 대한 모노클로날 항체
CN100443081C (zh) *	2005-04-05	2008-12-17	吴一心	木犀草素与一种铂类化疗药物联合用于制备抗肿瘤的药物
EP2345412A1 (en) *	2005-12-02	2011-07-20	The Johns Hopkins University	Use of high-dose oxazaphosphorine drugs for treating immune disorders
EP1991237B1 (en) *	2005-12-13	2015-02-25	Bionumerik Pharmaceuticals, Inc.	Chemoprotective methods and compositions
EP2004175A4 (en) *	2006-03-16	2010-12-15	Bionumerik Pharmaceuticals Inc	COMPOUNDS AND FORMULATIONS FOR INCREASING THE EFFECT OF CANCER AND METHOD FOR THEIR USE
WO2008034071A2 (en)	2006-09-15	2008-03-20	The Johns Hopkins University	Method of identifying patients suitable for high-dose cyclophosphamide treatment
WO2008034076A2 (en)	2006-09-15	2008-03-20	The Johns Hopkins University	Cyclophosphamide in combination with immune therapeutics
WO2008034074A2 (en)	2006-09-15	2008-03-20	The Johns Hopkins University	Cyclosphosphamide in combination with anti-idiotypic vaccines
JP2010518088A (ja) *	2007-02-09	2010-05-27	ポニアードファーマシューティカルズ，インコーポレイテッド	カプセル化されたピコプラチン
TW200916094A (en) *	2007-06-27	2009-04-16	Poniard Pharmaceuticals Inc	Stabilized picoplatin dosage form
EP2178893A4 (en) *	2007-07-16	2012-09-19	Poniard Pharmaceuticals Inc	ORAL FORMULATIONS FOR PICOPLATIN
US8765368B2 (en) *	2007-09-17	2014-07-01	The University Of Toledo	Cancer risk biomarker
US9026372B2 (en) *	2007-11-21	2015-05-05	Accentia Biopharmaceuticals, Inc.	Methods for providing a system of care for a high-dose oxazaphosphorine drug regimen
WO2009067699A2 (en) *	2007-11-21	2009-05-28	Accentia Biopharmaceuticals, Inc.	Methods for providing a system of care for an oxazaphosphorine drug regimen
WO2009099649A1 (en) *	2008-02-08	2009-08-13	Poniard Pharmaceuticals, Inc.	Use of picoplatin and bevacizumab to treat colorectal cancer
CA2717181C (en) *	2008-03-14	2013-10-15	Bionumerik Pharmaceuticals, Inc.	Treatment methods and compositions for lung cancer, adenocarcinoma, and other medical conditions
ES2476602T3 (es) *	2008-03-14	2014-07-15	Bionumerik Pharmaceuticals, Inc.	Composiciones y métodos quimioprotectores
CN102014891B (zh)	2008-03-14	2013-12-18	比奥纽默里克药物公司	增加癌症患者存活时间的化合物的组合物和使用方法
US9320760B2 (en) *	2008-03-14	2016-04-26	Bionumerik Pharmaceuticals, Inc.	Compositions and methods of use of compounds to increase cancer patient survival time
US20110064828A1 (en) *	2009-09-11	2011-03-17	Novelos Therapeutics, Incorporated	Treatment of metastatic tumors and other conditions
TWI438009B (zh) *	2010-02-19	2014-05-21	Teikoku Pharma Usa Inc	紫杉烷前－乳劑調配物及其製造與使用之方法
EA027666B1 (ru)	2010-05-03	2017-08-31	ТЕИКОКУ ФАРМА ЮСЭй, ИНК.	Неводные лекарственные средства в форме проэмульсии на основе таксанов и способы их приготовления и использования
BR112014017833A2 (pt)	2012-01-20	2021-03-23	Dennis Brown	Uso de hexitóis substituídos incluindo dianidrogalactitol e análogos para tratar doença neoplástica e células-tronco de câncer incluindo glioblastoma multiforme e meduloblastoma
HK1203420A1 (en) *	2012-07-19	2015-10-30	Vifor (International) Ltd.	Compositions comprising crosslinked cation-binding polymers
JO3685B1 (ar)	2012-10-01	2020-08-27	Teikoku Pharma Usa Inc	صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
WO2018232230A1 (en)	2017-06-15	2018-12-20	Cancer Advances Inc.	Compositions and methods for inducing humoral and cellular immunities against tumors and cancer
US12150978B2 (en)	2017-06-15	2024-11-26	Cancer Advances Inc.	Compositions and methods for preventing tumors and cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2806866C3 (de) *	1978-02-17	1981-02-12	Asta-Werke Ag Chemische Fabrik, 4800 Bielefeld	Verwendung von Salzen von Dithiodialkansulfonsäuren
US4310515A (en) *	1978-05-30	1982-01-12	Bristol-Myers Company	Pharmaceutical compositions of cisplatin
EP0334083B1 (de) *	1988-03-19	1991-07-24	ASTA Pharma Aktiengesellschaft	Ifosfamid-Mesna-Lyophilisat und Verfahren zu dessen Herstellung
US5227373A (en) *	1991-10-23	1993-07-13	Bristol-Myers Squibb Co.	Lyophilized ifosfamide compositions
JP3954115B2 (ja) *	1992-07-28	2007-08-08	アストラゼネカ・アクチエボラーグ	注射剤および注射剤キット
US5789000A (en) *	1994-11-14	1998-08-04	Bionumerik Pharmaceuticals, Inc.	Sterile aqueous parenteral formulations of cis-diammine dichloro platinum

1994
- 1994-11-14 US US08/338,379 patent/US5789000A/en not_active Expired - Lifetime
1995
- 1995-11-03 US US08/553,005 patent/US5902610A/en not_active Expired - Lifetime
- 1995-11-14 DE DE69530412T patent/DE69530412T2/de not_active Expired - Lifetime
- 1995-11-14 DK DK95939282T patent/DK0792154T3/da active
- 1995-11-14 CN CN951962310A patent/CN1165483B/zh not_active Expired - Lifetime
- 1995-11-14 ES ES95939282T patent/ES2191717T3/es not_active Expired - Lifetime
- 1995-11-14 CN CN2010102328968A patent/CN101987111A/zh active Pending
- 1995-11-14 KR KR1019970703171A patent/KR100411380B1/ko not_active Expired - Lifetime
- 1995-11-14 JP JP51574596A patent/JP4171526B2/ja not_active Expired - Fee Related
- 1995-11-14 AT AT95939282T patent/ATE237337T1/de active
- 1995-11-14 EP EP95939282A patent/EP0792154B1/en not_active Expired - Lifetime
- 1995-11-14 PT PT95939282T patent/PT792154E/pt unknown
- 1995-11-14 AU AU41168/96A patent/AU706181B2/en not_active Expired
- 1995-11-14 WO PCT/EP1995/004490 patent/WO1996014852A1/en not_active Ceased
- 1995-11-14 CA CA002202170A patent/CA2202170C/en not_active Expired - Lifetime
1997
- 1997-04-18 US US08/844,544 patent/US5866617A/en not_active Expired - Lifetime
- 1997-04-30 US US08/848,361 patent/US5866615A/en not_active Expired - Lifetime
- 1997-06-18 US US08/878,244 patent/US5866169A/en not_active Expired - Lifetime
2008
- 2008-02-28 JP JP2008047977A patent/JP2008133304A/ja active Pending
2012
- 2012-08-02 JP JP2012172119A patent/JP2012211198A/ja active Pending

Also Published As

Publication number	Publication date
US5866617A (en)	1999-02-02
AU706181B2 (en)	1999-06-10
KR100411380B1 (ko)	2004-04-30
JP2008133304A (ja)	2008-06-12
AU4116896A (en)	1996-06-06
CA2202170A1 (en)	1996-05-23
JP4171526B2 (ja)	2008-10-22
US5866169A (en)	1999-02-02
ES2191717T3 (es)	2003-09-16
DE69530412T2 (de)	2003-10-30
US5902610A (en)	1999-05-11
JP2012211198A (ja)	2012-11-01
CN101987111A (zh)	2011-03-23
MX9703460A (es)	1997-07-31
PT792154E (pt)	2003-09-30
ATE237337T1 (de)	2003-05-15
CN1165483B (zh)	2012-09-05
EP0792154B1 (en)	2003-04-16
US5789000A (en)	1998-08-04
JPH10509143A (ja)	1998-09-08
CA2202170C (en)	2007-04-10
WO1996014852A1 (en)	1996-05-23
DE69530412D1 (de)	2003-05-22
CN1165483A (zh)	1997-11-19
US5866615A (en)	1999-02-02
EP0792154A1 (en)	1997-09-03
KR970706830A (ko)	1997-12-01

Publication	Publication Date	Title
DK0792154T3 (da)	2003-08-04	Sammensætning af cisplatin i kombination med 2,2'-dithio-bis(ethansulfonat) (dimesna)
GR3017282T3 (en)	1995-11-30	Novel arylpyridazines, their manufacture, use and medicaments containing them.
TR200003333T2 (tr)	2001-02-21	Ensülin direngenliği ve hiperglisemi tedavisinde yararlı benzotiyofenler
PT1025845E (pt)	2003-03-31	Terapia com hidromorfona
CY1116988T1 (el)	2017-04-05	Βητα-l-2'-δεοξυ-νουκλεοζιτες για την θεραπεια ηπατιτιδας β
ES2056180T3 (es)	1994-10-01	Nuevos derivados de 2'-halometiliden, 2'-eteniliden y 2'-etinil citidina.
AU4484989A (en)	1990-06-12	Water soluble 1,2-diaminocyclohexane platinum (iv) complexes as antitumor agents
BR0016553A (pt)	2002-09-17	2-(1h-indol-3-il)-2-oxo-acetamidas com atividades antitumor
GR3003068T3 (en)	1993-02-17	(2,2-bis(aminomethyl)-1,3-propanediol-n,n')platinum complexes
DE69510545D1 (de)	1999-08-05	Cck oder gastrin modulierende 5-heterocyclicyl-1,5-benzodiazepine
DE69940551D1 (de)	2009-04-23	Mercaptane und disulfide
IE820976L (en)	1983-02-21	4'-halo-4'-deoxysucrose derivatives
DE3769910D1 (de)	1991-06-13	Verwendung von n, n'-bis-l-aminosaeure-l-cystinpeptiden in aminosaeure-praeparaten fuer orale und parenterale ernaehrung.
ES2020953B3 (es)	1991-10-16	Complejos de tetrahidro-3,4-furanodiamina-n-n'platino.
TR199900153T2 (xx)	1999-04-21	H�cre �o�almas�n� �nlemek i�in ikame edilmi� bisindolilmaleimitler.
NO20006699D0 (no)	2000-12-29	Forbindelser med veksthormonfrigjörende egenskaper
GB9420747D0 (en)	1994-11-30	1,5 benzodiazepine derivatives
DK0957920T3 (da)	2002-04-02	Reduktion af carboplatins toksiske effekt under anvendelse af dithioethere
EP0118565A4 (en)	1985-04-03	1,4-METHANO-2-BENZAZEPINE DERIVATIVES.
TR199701605A2 (xx)	1998-07-21	S�lfonamid-substit�e edilmi� bile�ikler
DE69807200D1 (de)	2002-09-19	Inklusionskomplexe in waessriger loesung
ATE231838T1 (de)	2003-02-15	N,n'-diacylthiocystine
NO20012169L (no)	2001-05-02	Forbindelser med veksthormonfrigjörende egenskaper
FI853708L (fi)	1985-09-26	Svaorantaendlig, biologiskt soenderfallande funktionell vaetska.
AR024131A1 (es)	2002-09-04	3,6-dihidro-pirazolo[3,4-d] [1,2,3] triazin-4-onas de efecto anticonvulsivo, procedimientos para su preparacion, su utilizacion para la preparacion demedicamentos y las composiciones farmaceuticas que los contienen